In which Windtree(WINT) remembers it is a drug company after all, and says something Clinical before lunch
A whimsical tale of finance and pharmaceuticals, as told in the Hundred Acre Nasdaq.
One day in the Hundred Acre Nasdaq, Windtree the Pooh awoke to a rather curious thing:
A press release. It was early, and quite serious.
And it said—though in a rather biotech-y sort of way—that Windtree had remembered something Very Important:
“Oh bother,” said Pooh, scratching his ticker symbol. “It seems I’m still a drug company.”
Windtree the Pooh had, for some time, been doing Very Exciting Things.
He had met a creature called Kraken and made plans to go treasure-hunting for something called BNB.
He had promised to buy environmental companies and maybe even turn into one himself.
There were dollars promised from mysterious trees that grew equity lines of credit, and nobody was quite sure if they were real.
But then, on this particular morning, Pooh remembered a thing he had left behind:
“My clinical program,” said Pooh.
“I had a drug. I quite liked it. I called it istaroxime.”
And indeed, the press release said that istaroxime had done something moderately positive in a Very Small Study.
There were some biomarkers that changed, and a few things that maybe looked better,
though Eeyore (who follows the biotech sector closely) said:
“Well, at least it didn’t get worse. That’s something.”
Piglet, who handles Regulatory Strategy and Press Relations, said:
“This proves we are still a serious pharmaceutical bear.”
“Yes,” said Owl. “But only if someone licenses it.”
“And only if they pay,” added Rabbit, who watches the cash runway.
Windtree the Pooh looked at his reflection in a puddle of diluted stock and asked himself:
“Am I a biotech bear with a crypto plan? Or a crypto bear with a biotech past?”
“I suppose I’m just Windtree,” he said, “and today, I remember that.”
Then he paused.
“…And also, I’m still very hungry.”
And so Windtree the Pooh wandered off into the rest of the trading day,
pondering how to monetize his clinical data,
his token strategy,
and maybe—just maybe—his royalties from something he licensed to a donkey years ago.
The End
(Or at least, until the next press release)